Company profile · free preview
ResMed
RMD · Updated 11/13/2026
Revenue
$5.7B
Fiscal 2026
Net income
$1.5B
Fiscal 2026
Free cash flow
$1.6B
Fiscal 2026
Net cash / (debt)
—
Fiscal 2026
Five-year financials
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $5.7B | $5.1B | $4.7B | $4.2B | $3.6B |
| Net income | $1.5B | $1.4B | $1.0B | $897.6M | $779.4M |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | $1.8B | $1.8B | $1.4B | $693.3M | $351.1M |
| Free cash flow | $1.6B | $1.7B | $1.3B | $573.6M | $216.3M |
| Cash | $1.5B | $1.2B | $238.4M | $227.9M | $273.7M |
| Total debt | — | — | — | — | — |
Financial trends
Historical · FY2022–FY2026
Source: Reported annual filings (10-K / 20-F) and provider data. Fiscal years as reported; margins are calculated from the reported figures shown.
Want the story behind these numbers? Ask Osiris anything about ResMed's filings — free.
Create free accountWhere the cash went
Cumulative, fiscal 2022–2026, straight from the reported cash-flow statements.
Reinvested in capex
10.0%
of operating cash flow
Returned to owners
—
of free cash flow (buybacks + dividends)
Diluted share count
—
change 2022–2026
| Operating cash flow | $6.0B |
| Capital expenditure | ($600.1M) |
| Free cash flow | $5.4B |
| Share buybacks | — |
| Dividends paid | — |
| Acquisitions (net) | — |
| Net debt issued / (repaid) | — |
| Stock-based compensation (non-cash) | — |
"—" means a year didn't report that line, so no total is shown rather than an estimate.
ResMed return on capital (fiscal 2026)
ROIC
20.7%
Return on capital
21.4%
Return on equity
24.3%
Return on assets
17.8%
Gross margin
61.1%
Operating margin
33.8%
Net debt / EBITDA
-0.38x
ResMed insider buying and selling
Recent open-market trades reported on Form 4. Context only — not a reason to buy or sell.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-23 | Rider Michael J | Sale | 400 | $255.00 |
| 2026-10-07 | Farrell Michael J. | Sale | 4,991 | $226.33 |
| 2026-09-08 | Farrell Michael J. | Sale | 4,991 | $222.44 |
| 2026-09-02 | FARRELL PETER C | Sale | 970 | $234.73 |
SEC filings
No filings stored yet.
Ask anything about ResMed's filings
"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.
Start researching free